CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Lung Cancer Community: 'This Is Our Fight'

Published: Tue, 17 Oct 2017 14:19:58 EDT
At the premier gathering of the lung cancer community, the first plenary session speaker insisted: 'We cannot deal with lung cancer and not fight against tobacco.'
Medscape Medical News

Eating More Nuts Could Protect Against Type 2 Diabetes

Published: Tue, 17 Oct 2017 13:36:14 EDT
Ensuring adequate daily intake of a fatty acid found in vegetable oils and nuts could help protect against type 2 diabetes, suggest the results of a pooled analysis of 20 prospective studies.
Medscape Medical News

Trump's Pick for Drug Czar Pulls Out After Investigation

Published: Tue, 17 Oct 2017 13:33:08 EDT
The decision follows a report by the Washington Post and 60 Minutes that showed Rep. Tom Marino spearheaded legislation that made it harder for the government to police the pharmaceutical industry.
Medscape Medical News
Displaying results 1-3 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial

Published: Tue, 17 Oct 2017 12:44:55 +0000
Five months ago, Johnson & Johnson painted sirukumab and talacotuzumab as part of a wave of blockbusters-in-waiting that would drive growth for years to come. Today, J&J abandoned plans to win approval of its once-hyped rheumatoid arthritis drug sirukumab and stopped a phase 3 trial of talacotuzumab in acute myeloid leukemia (AML).

Gemini taps A-list VCs for $42M to fuel AMD R&D

Published: Tue, 17 Oct 2017 10:55:43 +0000
Atlas Venture, Lightstone Ventures and OrbiMed have joined up to lead a $42.5 million investment in Gemini Therapeutics. The VCs put up the series A funds to equip Gemini to turn advances in our understanding of the genetics of age-related macular degeneration (AMD) into a drug pipeline.

AstraZeneca builds case for adding savolitinib to Iressa, Tagrisso

Published: Tue, 17 Oct 2017 10:25:51 +0000
AstraZeneca has posted preliminary phase 1b/2 data on the use of savolitinib in combination with Iressa or Tagrisso. Adding the MET tyrosine kinase inhibitor (TKI) to the approved drugs triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.
Displaying results 1-3 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top